The effective S-4 and this incorporation filing signal the merger is progressing toward a shareholder vote and closing. Monitor for the record date, proxy mailing, and shareholder meeting announcement.
CMMB drugs
CMMB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $1.18entry
- T+1 · 13d ago +4.24%α +2.59% · $1.23
- T+5 · 7d ago +13.98%α +14.57% · $1.35
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Chemomab Therapeutics filed a Form 6-K to incorporate by reference into its registration statements the S-4 registration statement for its pending merger with Scipher Medicine Corporation, which was declared effective on October 30, 2026. The filing includes audited and unaudited financial statements of both companies and pro forma combined financial information. This is a procedural step advancing the merger, which was originally announced on July 7, 2026.
Key Facts
- Chemomab entered into a merger agreement on July 7, 2026 with Snowdrift Parent Corporation, Snowdrift Sub Corp., Elderwood Ltd. and Scipher Medicine Corporation.
- The S-4 registration statement was declared effective by the SEC on October 30, 2026.
- This 6-K incorporates by reference selected definitions, business descriptions, financial statements, and pro forma combined financial information from the S-4 into Chemomab's existing F-3 and S-8 registration statements.
- The consent of Deloitte & Touche LLP, Scipher's independent auditor, is filed as Exhibit 23.1.
Financial Impact
No financial figures stated in this filing; the merger consideration is not disclosed here.
Risk Factors
- Merger may not close if conditions are not satisfied or if shareholders do not approve.
- Chemomab has a market cap of $9M and the deal structure is not detailed here; post-merger dilution and cash position are unknown.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004976 |
| Exhibit: exhibit_23-1.htm | 0001178913-26-004976 |
| Document: 0001178913-26-004976-index-headers.html | 0001178913-26-004976 |
| Document: 0001178913-26-004976-index.html | 0001178913-26-004976 |
| Document: 0001178913-26-004976.txt | 0001178913-26-004976 |
| Earnings Context (Synthetic; results releases only) | 0001178913-26-004976 |
Track record
15 reports on CMMB
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +33.01% at T+60 after the Aug 19, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13D Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 10, 20266d ago DEFA14A Neutral 5/10 Entry $1.35 Now $1.62 +20.00% settles Feb 9
- Nov 3, 202613d ago 6-K Neutral 4/10 Viewing Entry $1.18 Now $1.62 +37.29% settles Feb 1
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 30, 202617d ago DEFM14A Neutral 6/10 Entry $1.18 Now $1.62 +37.29% settles Jan 29
- Oct 19, 202628d ago 6-K Neutral 3/10 Entry $1.18 Now $1.62 +37.29% settles Jan 15
- Sep 30, 20266w ago 6-K Neutral 4/10 Entry $1.30 Now $1.62 +24.62% settles Dec 28
- Aug 19, 202612w ago 6-K Neutral 6/10 Entry $2.09 to $1.40 Now $1.62 −22.49% ▼ −33.01% −31.46% vs SPY
- Aug 19, 202612w ago Press Release Bearish 6/10 Entry $2.09 to $1.40 Now $1.62 +22.49% ▲ +33.01% +31.46% vs SPY
- Jul 8, 202618w ago 6-K Bullish 7/10 Entry $1.97 to $1.19 Now $1.62 −17.77% ▼ −39.59% −41.91% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers